Clinical breast cancer · 2026
Despite Advances, Repeat Breast-Conserving Surgery Rates Persist: A 25-Year National Analysis of Breast-Conserving Surgery in Australia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sejka Magdalena, Skandarajah Anita, Saunders Christobel
Аннотация
UNLABELLED: Using Australian Medicare Benefits Schedule data from 2000-2024, this national study examined repeat breastconserving surgery after initial excision for breast cancer. Repeat procedures remained persistently high (18.6%) despite evolving margin guidelines and surgical advances, with marked interstate variation. Younger patients had higher repeat surgery rates, and estimated annual system costs exceeded AUD $12 million.
BACKGROUND: Re-excision following breast-conserving surgery (BCS) remains a key indicator of surgical quality. Although adoption of the 2014 Society of Surgical Oncology and American Society for Radiation Oncology (SSO-ASTRO) "no tumor on ink" margin guideline, advances in imaging and oncoplastic techniques were expected to substantially reduce re-excision, national trends in Australia have not been well studied.
METHODS: We performed a retrospective population-based analysis using publicly available Medicare Benefits Schedule (MBS) procedural data from 2000 to 2024. Initial BCS procedures (MBS 31512 and, from 2023, 31513-31514) were used as denominators and re-excisions (MBS 31515) as numerators to calculate annual and state-based re-excision proportions. Demographic variation was assessed by age group and jurisdiction. Health-system costs were estimated using 2024 to 2025 National Weighted Activity Unit pricing.
RESULTS: Over 25 years, 171,715 BCS procedures and 31,987 repeat BCS were recorded, yielding a national repeat BCS proportion of 18.6%. Following publication of the SSO-ASTRO guideline, repeat BCS decreased modestly from 19.5% (2003-2013) to 18.1% (2014-2024; P < .001) but remained persistently high. Younger patients exhibited higher re-excision proportions, while substantial geographic variation was observed across states and territories (range 12.1%-24.1%). Mastectomy volumes stabilized over time while BCS volumes continued to rise. System-level costs attributable to re-excision exceeded AUD $12 million in 2024 alone.
CONCLUSIONS: Despite technical advances and consensus margin guidelines, national re-excision proportions after BCS have shown only marginal improvement over 25 years and remain geographically heterogeneous. Though our data cannot describe the true national re-excision rate, these findings indicate persistent system-level barriers to optimal margin clearance and highlight opportunities for national quality improvement.
BACKGROUND: Re-excision following breast-conserving surgery (BCS) remains a key indicator of surgical quality. Although adoption of the 2014 Society of Surgical Oncology and American Society for Radiation Oncology (SSO-ASTRO) "no tumor on ink" margin guideline, advances in imaging and oncoplastic techniques were expected to substantially reduce re-excision, national trends in Australia have not been well studied.
METHODS: We performed a retrospective population-based analysis using publicly available Medicare Benefits Schedule (MBS) procedural data from 2000 to 2024. Initial BCS procedures (MBS 31512 and, from 2023, 31513-31514) were used as denominators and re-excisions (MBS 31515) as numerators to calculate annual and state-based re-excision proportions. Demographic variation was assessed by age group and jurisdiction. Health-system costs were estimated using 2024 to 2025 National Weighted Activity Unit pricing.
RESULTS: Over 25 years, 171,715 BCS procedures and 31,987 repeat BCS were recorded, yielding a national repeat BCS proportion of 18.6%. Following publication of the SSO-ASTRO guideline, repeat BCS decreased modestly from 19.5% (2003-2013) to 18.1% (2014-2024; P < .001) but remained persistently high. Younger patients exhibited higher re-excision proportions, while substantial geographic variation was observed across states and territories (range 12.1%-24.1%). Mastectomy volumes stabilized over time while BCS volumes continued to rise. System-level costs attributable to re-excision exceeded AUD $12 million in 2024 alone.
CONCLUSIONS: Despite technical advances and consensus margin guidelines, national re-excision proportions after BCS have shown only marginal improvement over 25 years and remain geographically heterogeneous. Though our data cannot describe the true national re-excision rate, these findings indicate persistent system-level barriers to optimal margin clearance and highlight opportunities for national quality improvement.